Climb Bio, Inc. - 8-K Filing

Climb Bio reports Phase 1 data for CLYM116 showing >90% APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CLYM

Read the full article at SEC EDGAR

Part of the story Climb Bio, Inc. - 8-K Filing (3 articles)

More Regulatory news